Romosozumab in Postmenopausal Women with Low Bone Mineral Density
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody romosozumab binds to sclerostin and increases bone formation. METHODS: In a phase 2, multicenter, international, randomized, placebo-controlled, parallel-group, eight-group study, we evaluated the efficacy and safety of romosozumab over a 12-month period in 419 postmenopausal women, 55 to 85 years of age, who had low bone mineral density (a T score of -2.0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of the three sites). Participants were randomly assigned to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210 mg) or every 3 months (140 mg or 210 mg), subcutaneous placebo, or an open-label active comparator--oral alendronate (70 mg weekly) or subcutaneous teriparatide (20 μg daily). The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Secondary end points included percentage changes in bone mineral density at other sites and in markers of bone turnover. RESULTS: All dose levels of romosozumab were associated with significant increases in bone mineral density at the lumbar spine, including an increase of 11.3% with the 210-mg monthly dose, as compared with a decrease of 0.1% with placebo and increases of 4.1% with alendronate and 7.1% with teriparatide. Romosozumab was also associated with large increases in bone mineral density at the total hip and femoral neck, as well as transitory increases in bone-formation markers and sustained decreases in a bone-resorption marker. Except for mild, generally nonrecurring injection-site reactions with romosozumab, adverse events were similar among groups. CONCLUSIONS: In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption. (Funded by Amgen and UCB Pharma; ClinicalTrials.gov number, NCT00896532.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the simultaneous, acute increase in P1NP and reduction in CTx that we observed in the T3 group is qualitatively identical (but smaller in magnitude) to the effects of sclerostin inhibition on bone markers in humans22, and arguably pathognomonic of the consequences of sclerostin inhibition on bone.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
In the citing paper
“the time course of changes in bone formation we observed over 20 weeks of intermittent D + Q treatment in the T3 group is virtually identical (albeit smaller in magnitude) to that observed following treatment with the FDA-approved sclerostin inhibitor, romosozumab, where serum P1NP increased rapidly over the first 1–4 weeks following dosing and then returned to baseline by 24 weeks22.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Li, X., Ominsky, M. S., Niu, Q.-T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 936
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G., Stouch, B., Fang, L., & Posvar, E. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081206 · Cited by 784
Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton
Baron, R., & Rawadi, G. (2007) · Endocrinology · doi:10.1210/en.2007-0270 · Cited by 584
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
Loots, G. G., Kneissel, M., Keller, H., Baptist, M., Chang, J., Collette, N. M., Ovcharenko, D., Plajzer-Frick, I., & Rubin, E. M. (2005) · Genome Research · doi:10.1101/gr.3437105 · Cited by 442
Cited by
Items 801–900 of 1,000
Kumar, S., Beck, B. R., Nery, L., Byth, K., Elhindi, J., Wood, C., Fuller, O. K., Clifton-Bligh, R. J., & Girgis, C. M. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-086708 · Cited by 9
Inose, H., Takahashi, S., Teraguchi, M., Kato, T., Yamada, K., Yasuda, H., Terakawa, M., Minetama, M., Tomori, M., Nakagawa, Y., et al. (2024) · JBMR Plus · doi:10.1093/jbmrpl/ziae137 · Cited by 9
Martinez, J. P. D., Maraumont, T. A.-D., Sánchez, E. N., Cordero, L. M. C., & Yeh, E. J. (2025) · PLoS ONE · doi:10.1371/journal.pone.0299673 · Cited by 9
Early transition from short-term romosozumab to antiresorptive therapies: analysis of 26 cases
Everts‐Graber, J., Ferrari, S., Popp, A. W., Hars, M., Wenger, M., Oser, S., Studer, U., Steiner, C., Ziswiler, H., Schmid, G., et al. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01598-1 · Cited by 7
Sclerostin Blockade—A Dual Mode of Action After All?
Baschant, U., Henneicke, H., Hofbauer, L. C., & Rauner, M. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2988 · Cited by 8
Akhter, S., Qureshi, A. R., El-Khechen, H. A., Bozzo, A., Khan, M., Patel, R., Bhandari, M., & Aleem, I. S. (2020) · Bone Reports · doi:10.1016/j.bonr.2020.100728 · Cited by 7
New therapeutic options for bone diseases
Kocijan, R., Haschka, J., Feurstein, J., & Zwerina, J. (2021) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-020-00810-w · Cited by 7
McDonald, G. L. K., Wang, M., Hammond, C. L., & Bergen, D. J. M. (2021) · Biomolecules · doi:10.3390/biom11020277 · Cited by 7
Plasma Sclerostin in HIV-Infected Adults on Effective Antiretroviral Therapy
Erlandson, K. M., O’Riordan, M. A., Hileman, C. O., Rapaport, E. L., Labbato, D. E., Campbell, T., & McComsey, G. A. (2015) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0052 · Cited by 7
Gao, G.-D., Cui, J., Xie, Y.-Y., & Dong, J. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1440948 · Cited by 7
Lladó, B., García, M. S. M., Herrera, S. R., Dubuc, C. A. E., Mariscal, G., & Mateu, J. B. (2025) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000002241 · Cited by 6
Effect of romosozumab in premenopausal women with severe osteoporosis and anorexia nervosa
Fujimoto, K., Maki, N., Hashiba, D., Maeyama, T., Nakagawa, R., Arai, H., & Ohtori, S. (2023) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2023.10.001 · Cited by 6
Sahota, O., Narayanasamy, M. J., Bastounis, A., Paskins, Z., Bishop, S., Langley, T. E., Gittoes, N. J. L., Davis, S., Baily, A., Holmes, M., et al. (2024) · Health Technology Assessment · doi:10.3310/wypf0472 · Cited by 6
Lee, S., Hong, N., Cho, S., Shin, S., & Rhee, Y. (2025) · Osteoporosis International · doi:10.1007/s00198-024-07336-6 · Cited by 6
Mun, H. W., Lee, J. J., Shin, H., Kim, T.-H., Kim, S. W., & Oh, J. K. (2025) · Neurospine · doi:10.14245/ns.2449228.614 · Cited by 6
Nanomaterials‐Based Drug Delivery Systems for Therapeutic Applications in Osteoporosis
Shi, D., Li, Y., Tian, M., Xue, M., Wang, J., & An, H. (2025) · Advanced Biology · doi:10.1002/adbi.202400721 · Cited by 8
Henriksen, K., Thudium, C. S., Christiansen, C., & Karsdal, M. A. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1045415 · Cited by 7
Aspects of intercellular communication in bone and implications in therapy
Martin, T. J. (2021) · Bone · doi:10.1016/j.bone.2021.116148 · Cited by 8
Liu, J., Laster, A. J., Xu, X., Guo, H., Oates, M. K., & Gandra, S. R. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4439 · Cited by 8
Romosozumab-aqqg in the Treatment of Osteoporosis in a Patient With Hypophosphatasia
Khanjee, N., & Maalouf, N. M. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac159 · Cited by 6
Morley, J. E. (2016) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.11.001 · Cited by 6
A bibliometric research based on hotspots and frontier trends of denosumab
Ren, B., Ren, X., Wang, L., Tu, C., Zhang, W., Liu, Z., Qi, L., Wan, L., Pang, K., Tao, C., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.929223 · Cited by 6
Osteocytes and Their Messengers as Targets for the Treatment of Multiple Myeloma
Delgado‐Calle, J. (2017) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-017-9227-7 · Cited by 6
Trichilo, S., & Pivonka, P. (2017) · Courses and lectures · doi:10.1007/978-3-319-58845-2_2 · Cited by 6
Sclerostin antibodies as novel anabolic therapy for osteoporosis
Mamedova, E., Grebennikova, T. A., Belaya, Z. E., & Rozhinskaya, L. Y. (2019) · Osteoporosis and Bone Diseases · doi:10.14341/osteo10127 · Cited by 7
Watanabe, H., Ikoma, T., Sotome, S., & Okawa, A. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb02050h · Cited by 6
Liang, I., Brennan, S., Girgis, C. M., Hayden, A. J., Moujaber, T., Turner, S., Vasista, A., Grossmann, M., & Wong, P. K. K. (2025) · Cancer Medicine · doi:10.1002/cam4.70873 · Cited by 7
Damm, T., Libanati, C. R., Peña, J. A., Hanley, D. A., Bolognese, M. A., Recknor, C. P., & Glüer, C. (2025) · JBMR Plus · doi:10.1093/jbmrpl/ziaf119 · Cited by 5
Self-citationKaranjin counteracts OVX-induced bone loss by dual regulating bone remodeling
Ma, Q., Li, C., Lin, G., Shi, J., Wang, C., Wang, H., Cai, J., Zhang, Y., Li, J., Chang, M., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157099 · Cited by 6
Sabol, H. M., Anloague, A., Kaur, J., Bustamante-Gomez, C., Khan, S., Paxton, B. C., Nester, M. R., Hackney, J., Diaz‐delCastillo, M., Mann, D. C., et al. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00699-4 · Cited by 6
Papapoulos, S. E. (2014) · BoneKEy Reports · doi:10.1038/bonekey.2014.18 · Cited by 5
Surowiec, R. K., Battle, L., Schlecht, S. H., Wojtys, E. M., Caird, M. S., & Kozloff, K. M. (2020) · JBMR Plus · doi:10.1002/jbm4.10377 · Cited by 5
Chavassieux, P., Roux, J. P., Libanati, C. R., Shi, Y., & Chapurlat, R. D. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae118 · Cited by 6
Self-citationRethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?
Gavrilov, Z., & Lojk, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146924 · Cited by 7
EndoCompass project: research roadmap for calcium and bone endocrinology
Jähn, K., Zibar, K., Anastasilakis, A. D., Bertocchio, J., Brandi, M. L., Faßnacht, M., Cheung, M., Gevers, E. F., Gittoes, N. J. L., Mäkitie, O., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf064 · Cited by 6
A clinician's guide to the management of geriatric musculoskeletal disease: Part 1 - Osteoporosis
Feehan, J., Tripodi, N., Fleischmann, M., Zanker, J., & Duque, G. (2021) · International journal of osteopathic medicine · doi:10.1016/j.ijosm.2021.12.003 · Cited by 5
Simonini, M., Bologna, A., & Vezzoli, G. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-04110-9 · Cited by 5
Idiopathic Acquired Osteosclerosis in a Middle-Aged Woman With Systemic Lupus Erythematosus
Guañabens, N., Mumm, S. R., Gifre, L., Ruiz-Gaspà, S., Demertzis, J. L., Stolina, M., Novack, D. V., & Whyte, M. P. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2842 · Cited by 6
Osteoporosis: Prevention and Treatment
Zaheer, S., & LeBoff, M. S. (2016) · Cited by 8
Lessons from Bone Histomorphometry on the Mechanisms of Action of Osteoporosis Drugs
Zhou, H., & Dempster, D. W. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00076-5 · Cited by 5
Epigenetic Regulation of Sost/sclerostin Expression
del Real, Á., Riancho, J. A., & Delgado‐Calle, J. (2017) · Current Molecular Biology Reports · doi:10.1007/s40610-017-0063-9 · Cited by 5
Chen, W., Wasnik, S., Fu, Y.-W., Aranda, L., Rundle, C. H., Lau, K. ‐. W., Baylink, D. J., & Zhang, X. (2019) · Bone Reports · doi:10.1016/j.bonr.2019.100236 · Cited by 5
Sclerostin Inhibition in the Treatment of Osteoporosis
Baron, R., Gori, F., & Leder, B. Z. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-319-69287-6_19 · Cited by 6
Jakob, F. J. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1213-2245 · Cited by 5
Risks vs. benefits of switching therapy in patients with postmenopausal osteoporosis
Ishizu, H., Arita, K., Terkawi, M. A., Shimizu, T., & Iwasaki, N. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1956902 · Cited by 5
Advances in Diagnosis and Management of Childhood Osteoporosis
Lim, D., Moon, R. J., & Davies, J. H. (2022) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2022.2022-8-3 · Cited by 8
Where is bone science taking us?
Langdahl, B. L., Uitterlinden, A. G., & Ralston, S. H. (2022) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2022.101791 · Cited by 6
Self-citationVitamin D, Inflammation and Osteoporosis in Rheumatoid Arthritis
Sainaghi, P. P., & Gibbin, A. (2018) · The Open Rheumatology Journal · doi:10.2174/1874312901812010300 · Cited by 7
Surowiec, R. K., Battle, L., Ward, F. S., Schlecht, S. H., Khoury, B. M., Robbins, C. B., Wojtys, E. M., Caird, M. S., & Kozloff, K. M. (2019) · Bone · doi:10.1016/j.bone.2019.115118 · Cited by 7
Gingery, A., Subramaniam, M., Pitel, K. S., Li, X., Ke, H. Z., Turner, R. T., Iwaniec, U. T., & Hawse, J. R. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29500 · Cited by 5
Effects of Spinal Cord Injury and Related Conditions
Yarrow, J. F., & Cardozo, C. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11219-x · Cited by 5
Yavropoulou, M. P., Kasdagli, M., Makras, P., Diomatari, K.-M., Anastasilakis, A. D., Mitsikostas, D. D., Kassi, E. N., Sfikakis, P. P., & Kravvariti, E. (2023) · Maturitas · doi:10.1016/j.maturitas.2023.107874 · Cited by 4
Clinical challenges and considerations in pharmacotherapy of osteoporosis due to menopause
Palacios, S., Rodríguez, S. P. G., Prieto, M. S., & Fasero, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2383639 · Cited by 7
Schäfersküpper, M., Simon, A., Yorgan, T. A., von Brackel, F. N., Delsmann, M. M., Baranowsky, A., Gagelmann, N., Ayuk, F. A., Schinke, T., Amling, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55915-w · Cited by 5
Severe Osteoporosis With Pathogenic LRP5 Variant
Stringer, F., Sims, N. A., Sachithanandan, N., & Aleksova, J. (2024) · JCEM Case Reports · doi:10.1210/jcemcr/luae021 · Cited by 4
Gomes-Ferreira, P. H. S., Frigério, P. B., Duarte, N. D., de Moura, J., Monteiro, N. G., Fábris, A. L. D. S., & Okamoto, R. (2025) · Bioengineering · doi:10.3390/bioengineering12040358 · Cited by 4
Johnson, M. L. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2459 · Cited by 5
Sebastián, A., & Frassetto, L. A. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.04.027 · Cited by 6
Gaffney‐Stomberg, E., MacArthur, M. R., & McClung, J. P. (2017) · Biomarkers in disease · doi:10.1007/978-94-007-7693-7_27 · Cited by 7
Human Placental LRP5 and Sclerostin are Increased in Gestational Diabetes Mellitus Pregnancies
Papadopoulou, A., Thymara, E., Maratou, E., Kanellopoulos, G., Papaevangelou, V., Kalantaridou, S., Kanellakis, S., Triantafyllidou, P., Valsamakis, G., & Mastorakos, G. P. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad164 · Cited by 4
Hendrickx, G., Boudin, E., Mateiu, L. M., Yorgan, T. A., Steenackers, E., Kneissel, M., Krämer, I., Mortier, G. R., Schinke, T., & Hul, W. V. (2023) · Calcified Tissue International · doi:10.1007/s00223-023-01158-0 · Cited by 4
Al-Bogami, M. M., Alkhorayef, M. A., Byström, J., Akanle, O. A., Adhoubi, N. K. A., Jawad, A. S. M., & Mageed, R. A. (2015) · Saudi Medical Journal · doi:10.15537/smj.2015.11.12731 · Cited by 4
Great strides made but still further to go
Reid, I. R. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.143 · Cited by 4
Prevention and Treatment of Bone Disease in Systemic Lupus Erythematosus
Lin, T. K., & Grossman, J. M. (2016) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-016-0034-y · Cited by 4
Lane, N. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00101-7 · Cited by 5
Biologics for Osteoporosis: Where Do We Stand?
Gheita, T. A., & Fathi Hanan, M. (2018) · Journal of Musculoskeletal Disorders and Treatment · doi:10.23937/2572-3243.1510059 · Cited by 6
Kline, G. A., Orton, D. J., & Sadrzadeh, H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803412-5.00004-5 · Cited by 4
Bone histomorphometry in rodents
Ma, Y. L., Burr, D. B., & Erben, R. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00082-8 · Cited by 6
Chapurlat, R. D., & Genant, H. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00069-x · Cited by 7
Gómez-Moreno, M., Ramos-González, E. J., Castañeda‐Delgado, J. E., Castillo-Ortiz, J. D., Ramos-Remus, C., Zapata-Zúñiga, M., Méndez, J. A. T., Monsiváis-Urenda, A. E., Portales‐Pérez, D. P., Enciso‐Moreno, J. A., et al. (2020) · Human Immunology · doi:10.1016/j.humimm.2020.07.003 · Cited by 4
Uemura, Y., Sone, T., Tanaka, S., Miyazaki, T., Tsukiyama, M., Taguchi, A., Soen, S., Mori, S., Hagino, H., Sugimoto, T., et al. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1816537 · Cited by 4
Lessons from bone histomorphometry on the mechanisms of action of osteoporosis drugs
Zhou, H., & Dempster, D. W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00081-2 · Cited by 4
Hong, A. R., Yang, J., Lee, J. Y., Suh, J., Lee, Y., Kim, J., & Kim, S. W. (2022) · Calcified Tissue International · doi:10.1007/s00223-022-01013-8 · Cited by 4
Li, Z., Qiu, K., Zhao, J., Granger, K., Yu, H. M., Lewis, A. G., Myronovych, A., Toure, M. H., Hatsell, S. J., Economides, A. N., et al. (2023) · Bone · doi:10.1016/j.bone.2023.116682 · Cited by 4
Mathur, A. S., Gopalakrishnan, D., Shetty, S. K., Mehta, V., & Bagwe, S. (2022) · Journal of Head & Neck Physicians and Surgeons · doi:10.4103/jhnps.jhnps_48_22 · Cited by 4
Endocrinology research—reflecting on the past decade and looking to the next
Herold, K. C., Majzoub, J. A., Melmed, S. K., Pendergrass, M., & Schlumberger, M. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.164 · Cited by 4
Schett, G. A., & Bözec, A. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.009 · Cited by 4
Fragility Fractures in Chronic Kidney Disease: Assessment and Pharmacologic Management
Anpalahan, M., Venkatesan, S., & Anpalahan, A. (2014) · Advances in Nephrology · doi:10.1155/2014/727135 · Cited by 4
Romosozumab for the treatment of postmenopausal osteoporosis
Cosman, F., & Saag, K. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00080-0 · Cited by 5
Biology, Physiology, and Morphology of Bone
Schett, G. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1738-9.00004-9 · Cited by 4
Terpos, E., & Gavriatopoulou, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65375-8 · Cited by 4
Noh, M., Che, X., Jin, X., Lee, D.-K., Kim, H., Park, D. R., Lee, S. Y., Lee, H., Gardella, T. J., Choi, J., et al. (2024) · eLife · doi:10.7554/elife.97579 · Cited by 9
Noh, M., Che, X., Jin, X., Lee, D.-K., Kim, H., Park, D. R., Lee, S. Y., Lee, H., Gardella, T. J., Choi, J., et al. (2024) · eLife · doi:10.7554/elife.97579.1 · Cited by 4
Parvin, A., Sharma, A. R., Hasan, M. A., Sharma, G., Shawan, M. M. A. K., Seo, E. M., Hasan, M. M., & Lee, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1633318 · Cited by 3
Safety of Romosozumab in women with cancer and osteoporosis at high risk of fractures
Colle, R., Piasentier, A., Fanti, A., Gentile, L., Bodini, S., Vitale, V., Jaafar, S., Birtolo, M. F., Bertoldo, F., Mazziotti, G., et al. (2025) · Endocrine · doi:10.1007/s12020-025-04434-1 · Cited by 3
Efficacy comparison of 6-month romosozumab plus denosumab versus 12-month romosozumab in Koreans
Lee, S., Ahn, S. H., Kim, B., Lee, S. H., Kim, H. Y., Hong, S., & Koh, J. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf211 · Cited by 3
Treatment with romosozumab in patients with osteoporosis on maintenance hemodialysis
Sato, M. (2025) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-025-01651-6 · Cited by 3
Chen, L. K., Wang, Q., & Gu, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1732708 · Cited by 3
Zanchetta, M. B., Pernas, M. G., Jerkovich, F., Pingel, J., Schwartz, N., Erdociain, L., & Zanchetta, J. (2026) · Bone Reports · doi:10.1016/j.bonr.2026.101902 · Cited by 3
Self-citationUnlocking bone repair in osteoporosis by targeting the angiogenic niche
Chen, M., Wang, J., Wei, J., & Feng, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1790054 · Cited by 3
Semeraro, A., Chialà, A., Carafa, A., Fanizzi, R., Tano, E. D., Palmisano, M., Santoro, C., Dibenedetto, F., & Napoli, N. (2026) · Aging Clinical and Experimental Research · doi:10.1007/s40520-026-03391-7 · Cited by 1
Gibbons, B., Lubsen, J., & Martonffy, A. I. (2025) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2025.01.008 · Cited by 3
Zhou, B., Hu, J., Yu, Y., Sun, L., Wang, Y., Zhang, Q., Jiang, Y., Wang, O., Xing, X., Xia, W., et al. (2025) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13831 · Cited by 5
Kobayashi, T., Kobayakawa, T., & Nakamura, Y. (2025) · Bone · doi:10.1016/j.bone.2025.117708 · Cited by 3
Gronbach, M., Mitrach, F., Möller, S., Rother, S., Friebe, S., Mayr, S. G., Schnabelrauch, M., Hintze, V., Hacker, M. C., & Schulz‐Siegmund, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111037 · Cited by 3
Endocrinology of Bone and Growth Disorders
Farquharson, C., Stephen, L. A., & Wong, S. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00086-4 · Cited by 3
Schneider, G. K., & Ing, S. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac152 · Cited by 2
Rare and Common Variants in GALNT3 May Affect Bone Mass Independently of Phosphate Metabolism
Hassan, N., Gregson, C. L., Tang, H., van der Kamp, M. W., Leo, P., McInerney-Leo, A. M., Zheng, J., Brandi, M. L., TANG, J. C. Y., Fraser, W. D., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4795 · Cited by 4
Kobayakawa, T., Kanayama, Y., Hirano, Y., & Nakamura, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-73398-5 · Cited by 6
Delgado‐Calle, J., Pérez-Campo, F. M., & Riancho, J. (2014) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.4321/s1889-836x2014000400006 · Cited by 3
Metadata
- Authors
- McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., Katz, L., Maddox, J., Yang, Y.-C., Libanati, C., & Bone, H. G.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Amgen (United States) (US)
- KU Leuven (BE)
- National Institutes of Health (US)
- Centre hospitalier universitaire de Québec (CA)
- Aarhus University Hospital (DK)
- University of Liège (BE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-30
- Volume
- 370
- Issue
- 5
- Pages
- 412-420
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096627331
- Cited by
- 1,258
- References
- 16
- Citations by year
- 2026: 75 · 2025: 97 · 2024: 82 · 2023: 52 · 2022: 99 · 2021: 93 · 2020: 121 · 2019: 69 · 2018: 90 · 2017: 105 · 2016: 125 · 2015: 139 · 2014: 101
- FWCI
- 160.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- romosozumab, sclerostin, postmenopausal osteoporosis, osteopenia, bone mineral density, bone formation, bone resorption, alendronate, teriparatide, osteocytes, osteoblast activity, monoclonal antibodies, dose comparison, injection site reactions
- MeSH terms
- Aged, Aged, 80 and over, Antibodies, Monoclonal, Calcium, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Lumbar Vertebrae, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Least-Squares Analysis, Bone Remodeling, Teriparatide, Alendronate, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.